- Home
- APLS vs TMHC Comparison
APLS vs TMHC Comparison
Compare APLS & TMHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APLS | TMHC |
|---|---|---|
| Founded | 2009 | 1936 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.6B |
| IPO Year | 2015 | 2012 |
Fundamental Metrics
Financial Performance| Metric | APLS | TMHC |
|---|---|---|
| Price | $40.86 | $59.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 21 | 8 |
| Target Price | $32.71 | ★ $74.00 |
| AVG Volume (30 Days) | ★ 8.0M | 1.1M |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.50 | N/A |
| EPS | 0.20 | ★ 7.77 |
| Revenue | $1,003,782,000.00 | ★ $4,762,059,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.19 | $8.96 |
| P/E Ratio | $204.20 | ★ $7.77 |
| Revenue Growth | ★ 28.46 | N/A |
| 52 Week Low | $16.10 | $54.26 |
| 52 Week High | $40.87 | $72.27 |
Technical Indicators
Market Signals| Indicator | APLS | TMHC |
|---|---|---|
| Relative Strength Index (RSI) | 87.65 | 50.23 |
| Support Level | $18.53 | $59.74 |
| Resistance Level | N/A | $65.18 |
| Average True Range (ATR) | 0.27 | 1.64 |
| MACD | 1.31 | 0.43 |
| Stochastic Oscillator | 99.94 | 85.10 |
Price Performance
Historical ComparisonAbout APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
About TMHC Taylor Morrison Home Corporation
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.